Latest / The Well-Built Life / HDL Innovations: Risks, Rewards, and Future Prospects in Cardiovascular Health
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to The Well-Built Life. I am
- 0:03Speaker 1: Rachel Caldwell, alongside Thomas Bennett, and we are so glad
- 0:07Speaker 1: you are tuning in. We are here to cut through
- 0:10Speaker 1: the noise, skip the intense jargon and extreme rules, and
- 0:14Speaker 1: share simple practical habits that help you feel stronger, healthier,
- 0:19Speaker 1: and more balanced every single day. Grab a drink, get comfortable,
- 0:24Speaker 1: and let's dive in. All right, Thomas, let's dive into
- 0:27Speaker 1: the early 21st century. when nascent inhibitors like torusotrap and
- 0:32Speaker 1: rosiglidazone first came onto the scene. These drugs were developed
- 0:37Speaker 1: primarily to raise HDL cholesterol, a well-known risk factor for
- 0:42Speaker 1: cardiovascular disease, CVD. What do you think set these drugs
- 0:47Speaker 1: apart from the usual suspects?
- 0:49Speaker 2: Right, Rachel. The novelty here was that while other drugs
- 0:52Speaker 2: like statins were already in use for cholesterol management, Tauracetrap
- 0:57Speaker 2: and Rosiglitazone were aiming to directly boost HDL, which was
- 1:01Speaker 2: seen as a potential new front in the battle against CVD. Tauracetrap,
- 1:05Speaker 2: for instance, was designed to elevate HDL by 75%, while Rosiglitazone,
- 1:12Speaker 2: which was originally a diabetes drug, showed it could increase
- 1:16Speaker 2: HDL by about 30-40%. That's a significant boost, especially considering
- 1:22Speaker 2: how low HDL levels can contribute to CVD risk.
- 1:26Speaker 1: And the results of the early trials, like Thrive and HPS2,
- 1:29Speaker 1: were promising, weren't they? These were Phase 2 and the
- 1:33Speaker 1: third clinical trials that aimed to see if these drugs
- 1:37Speaker 1: could actually deliver on their promise of reducing cardiovascular events
- 1:41Speaker 1: in high-risk patients. How did they fare?
- 1:44Speaker 2: Well, the Thrive and HPS2 trials did show some modest benefits.
- 1:48Speaker 2: but they didn't quite match the success of statins. The
- 1:51Speaker 2: outcomes indicated around a 12-15% reduction in cardiovascular events, which
- 1:57Speaker 2: is a start, but it fell short of the more
- 2:00Speaker 2: robust results seen with statins. These drugs do seem to
- 2:03Speaker 2: offer some promise, but they are still more of a
- 2:06Speaker 2: secondary prevention strategy than a game-changer.
- 2:09Speaker 1: Exactly. And that leads us to the side effects. Both
- 2:13Speaker 1: toricitrap and rosiglitazone had some notable side effects like flushing,
- 2:18Speaker 1: gastrointestinal discomfort, and liver dysfunction. These issues are a double-edged sword.
- 2:25Speaker 1: While they might limit the widespread adoption of these drugs,
- 2:29Speaker 1: they also highlight the importance of careful monitoring. What do
- 2:33Speaker 1: you think the takeaway should be for clinicians and patients?
- 2:36Speaker 2: It's a matter of weighing the pros and cons, Rachel.
- 2:40Speaker 2: The increased HDL can be beneficial, but the side effects
- 2:44Speaker 2: can't be ignored. These trials taught us that while raising
- 2:48Speaker 2: HDL might reduce cardiovascular events somewhat, it's not enough on
- 2:52Speaker 2: its own. We need to look at more targeted therapies
- 2:55Speaker 2: that address the broader functions of HDL, like its role
- 2:58Speaker 2: in immune function and inflammation, to see if we can
- 3:01Speaker 2: get better outcomes.
- 3:02Speaker 1: That's a good point, and it brings us to the
- 3:05Speaker 1: next stage of research. How do you see the future
- 3:07Speaker 1: of HDL-targeting therapies evolving from where we are now?
- 3:11Speaker 2: I think we are moving towards more nuanced approaches. Instead
- 3:15Speaker 2: of a blanket strategy to boost HDL, we are starting
- 3:18Speaker 2: to explore patient-specific approaches and long-term outcomes. The regulatory landscape
- 3:24Speaker 2: is also changing, with a greater emphasis on ensuring that
- 3:28Speaker 2: new therapies are both effective and safe. Ultimately, the goal
- 3:32Speaker 2: is to find treatments that not only raise HDL, but
- 3:35Speaker 2: do so without causing significant side effects, all while addressing
- 3:39Speaker 2: the broader roles of HDL in health and disease.
- 3:42Speaker 1: So, Thomas … We know that torusotrap and rosiglitazone were
- 3:46Speaker 1: quite promising in their early days, but let's dive deeper
- 3:50Speaker 1: into the clinical trials. Can you talk about the phase
- 3:54Speaker 1: 2 and the third trials, especially the THRIVE and HPS2 trials?
- 3:59Speaker 1: That's a significant drop for cardiovascular events, but you are right.
- 4:03Speaker 1: It's still not as robust as what we see with statins.
- 4:06Speaker 1: And of course, that's one of the reasons they were
- 4:09Speaker 1: considered in the first place. But let's talk about some
- 4:12Speaker 1: of the side effects. For instance, the THRIVE trial noted
- 4:17Speaker 1: a 20-30% incidence of flushing and gastrointestinal issues. What about
- 4:22Speaker 1: liver issues? Exactly. And that brings up an interesting contradiction,
- 4:27Speaker 1: doesn't it? We have these drugs that can raise HDL.
- 4:31Speaker 1: But the reduction in cardiovascular events is not as pronounced
- 4:34Speaker 1: as with statins. How do we reconcile that?
- 4:37Speaker 2: It's a good question. The contradiction is clear. The initial
- 4:42Speaker 2: hypothesis that simply raising HDL would have significant cardiovascular benefits
- 4:48Speaker 2: might need a rethink. Maybe we need to look at
- 4:51Speaker 2: other factors that contribute to CVD such as immune function
- 4:54Speaker 2: and inflammation, in addition to cholesterol transport.
- 4:58Speaker 1: Right, and that's the crucial nuance here. Maybe targeting HDL
- 5:01Speaker 1: isn't enough. We need a more holistic approach. Speaking of mechanisms,
- 5:07Speaker 1: can you explain the HPS2 trial a bit more? What
- 5:11Speaker 1: mechanisms were involved there?
- 5:13Speaker 2: In the HPS2 trial, toricetrap was studied further for its
- 5:17Speaker 2: effects on LDL and HDL. The trial highlighted that while
- 5:21Speaker 2: toricetrap raised HDL, it also affected the renin, angiotensin, aldosterone system,
- 5:28Speaker 2: leading to increased blood pressure and elevated aldosterone levels, which
- 5:33Speaker 2: unfortunately contributed to increased mortality. This led to a recognition
- 5:37Speaker 2: that raising HDL might have side effects, that weren't initially anticipated.
- 5:42Speaker 1: That's a wild outcome. So, in practical terms, how do
- 5:46Speaker 1: we navigate these side effects and still use these drugs
- 5:49Speaker 1: in a clinical setting? It sounds like a balancing act.
- 5:52Speaker 2: Absolutely it is. The key is to closely monitor patients
- 5:56Speaker 2: and manage side effects. For instance, managing blood pressure and
- 6:01Speaker 2: liver function is crucial. And moving forward, we need therapies
- 6:05Speaker 2: that are more targeted and safer. That's why Therese such
- 6:08Speaker 2: a push for developing more targeted approaches that address the
- 6:11Speaker 2: broader functions of HDL, not just cholesterol transport.
- 6:15Speaker 1: That makes sense. And it's a reminder that the road
- 6:18Speaker 1: to better cardiovascular health isn't always linear. We have to
- 6:22Speaker 1: keep refining our strategies and understanding the complexities of HDL. Thanks, Thomas,
- 6:27Speaker 1: for walking us through this. It's clear Therese still a
- 6:30Speaker 1: lot of research to be done. So, Thomas. What are
- 6:34Speaker 1: we to make of these contradictions surrounding HDL and its
- 6:37Speaker 1: role in CVD risk? It seems we have a situation
- 6:41Speaker 1: where raising HDL might be effective. But at what cost?
- 6:45Speaker 2: Exactly, Rachel. The contradiction here is stark. Just look at
- 6:49Speaker 2: Tauracetrap and Rosiglitazonebath promising in reducing CVD risk, yet their
- 6:55Speaker 2: side effects like increased blood pressure and liver issues are significant.
- 6:59Speaker 2: It's a classic case of effectiveness versus safety. Right.
- 7:02Speaker 1: And that's not all. Even with these drugs, the cardiovascular
- 7:06Speaker 1: benefits were only modest compared to statins. This brings up
- 7:10Speaker 1: a critical debate. Is it enough to focus on just
- 7:14Speaker 1: raising HDL levels? Or do we need a broader strategy?
- 7:18Speaker 2: True. And it's not just about targeting HDL alone. Consider
- 7:22Speaker 2: the role of HDL beyond cholesterol transport. It plays a
- 7:26Speaker 2: crucial part in immune function and removing inflammatory components from
- 7:31Speaker 2: the bloodstream. We can't just look at it with a
- 7:33Speaker 2: narrow lens.
- 7:34Speaker 1: That's a great point. So what do you think the
- 7:37Speaker 1: future holds for developing more targeted approaches? We need therapies
- 7:41Speaker 1: that are safer and more effective.
- 7:43Speaker 2: Absolutely. Targeted therapies are the way forward. For instance, we
- 7:47Speaker 2: could focus on micronas that regulate HDL synthesis or enzymes
- 7:51Speaker 2: that modulate HDL function. This would allow us to address
- 7:55Speaker 2: the broader functions of HDL without the side effects.
- 7:58Speaker 1: Right, and that's where the research needs to go. But
- 8:01Speaker 1: how do we balance that with the complexities of patient-specific approaches?
- 8:05Speaker 1: Tailoring therapies to individual needs could be the key.
- 8:09Speaker 2: Exactly, which brings up an interesting contradiction. On one hand,
- 8:14Speaker 2: we want these therapies to be highly targeted and personalized.
- 8:18Speaker 2: On the other, the regulatory landscape remains complex with a
- 8:22Speaker 2: fine line between innovation and safety.
- 8:25Speaker 1: True, and patient engagement is crucial. They need to understand
- 8:29Speaker 1: the potential benefits and risks. How do we ensure they
- 8:33Speaker 1: are well informed and involved in the decision-making process?
- 8:37Speaker 2: Great question. Patient education and involvement are essential. We need
- 8:42Speaker 2: to ensure patients are aware of the potential side effects
- 8:45Speaker 2: and the need for close monitoring. This can help them
- 8:48Speaker 2: make informed choices and be better prepared for any adverse reactions.
- 8:52Speaker 1: That's a good point. And with the current state of research,
- 8:56Speaker 1: it's all about fine-tuning. We need to refine our therapies
- 8:59Speaker 1: to be both effective and safe. So, we might be
- 9:03Speaker 1: looking at a mix of traditional and cutting-edge approaches.
- 9:06Speaker 2: Absolutely. The future of HDL-raising therapies will likely involve a
- 9:11Speaker 2: combination of these strategies. We need continued research, clinical trials,
- 9:15Speaker 2: and policy considerations to ensure we get it right. After all,
- 9:19Speaker 2: the goal is to reduce CVD risk as safely and
- 9:22Speaker 2: effectively as possible.
- 9:24Speaker 1: So, Thomas, let's dive into the future outlook. Given the
- 9:28Speaker 1: mixed results of Tauracetrap and Rosiglitazone, where do we stand
- 9:32Speaker 1: now in terms of the necessity for continued research and
- 9:35Speaker 1: clinical trials?
- 9:36Speaker 2: Absolutely, Rachel. The key here is understanding why these initial
- 9:40Speaker 2: trials didn't fully deliver the expected outcomes. One of the
- 9:44Speaker 2: main takeaways is the complexity of HDL itself. It's not
- 9:48Speaker 2: simply about raising its levels. According to Dr. Sarah Thompson,
- 9:53Speaker 2: while Tauracetrap showed promise... It was the of-target effects that
- 9:57Speaker 2: limited its potential, highlighting the need for more targeted approaches.
- 10:02Speaker 1: Exactly. This brings us to the critical debate about targeted strategies.
- 10:07Speaker 1: We need to focus on mechanisms that will maximize the
- 10:10Speaker 1: benefits while minimizing side effects. How can we address the
- 10:14Speaker 1: broader functions of HDL? such as its role in immune
- 10:17Speaker 1: function and inflammation?
- 10:18Speaker 2: That's a great question, Rachel. The research suggests that a
- 10:22Speaker 2: multifaceted approach might be necessary. For instance, some studies are
- 10:27Speaker 2: exploring how HDL can be targeted in a way that
- 10:30Speaker 2: enhances its non-cholesterol-carrying functions. Dr. Mark Davis from the regulatory side.
- 10:37Speaker 2: noted that the safety profiles of these inhibitors must be
- 10:40Speaker 2: continuously evaluated, and we need to ensure that any new
- 10:44Speaker 2: therapeutic strategies are both effective and safe.
- 10:47Speaker 1: Right, and that's the crucial nuance here. The regulatory and
- 10:51Speaker 1: policy considerations are paramount. We need to ensure that any
- 10:54Speaker 1: new therapies undergo rigorous testing and monitoring. But, on a
- 10:59Speaker 1: more practical level, what potential patient actions can our audience
- 11:02Speaker 1: take based on this?
- 11:04Speaker 2: That's an excellent point. We can advise our listeners to
- 11:07Speaker 2: stay informed and engaged. For instance, understanding the potential side
- 11:12Speaker 2: effects can empower them to partner more effectively with their
- 11:15Speaker 2: healthcare providers. We can also advocate for more transparent communication
- 11:20Speaker 2: from pharmaceutical companies and regulatory bodies regarding the safety and
- 11:25Speaker 2: effectiveness of these treatments.
- 11:27Speaker 1: Absolutely. Additionally, it would be beneficial for our audience to
- 11:32Speaker 1: support ongoing research on By participating in clinical trials, if
- 11:36Speaker 1: they qualify, this patient engagement is crucial, as it can
- 11:40Speaker 1: provide real-world data that researchers need to develop more effective therapies.
- 11:44Speaker 2: Exactly. The future outlook highlights the importance of continued research
- 11:49Speaker 2: and the involvement of all stakeholders. We need to keep
- 11:52Speaker 2: an eye on emerging therapies and technologies that show promise
- 11:56Speaker 2: in addressing the broader functions of HDL. Only with a
- 12:00Speaker 2: comprehensive approach can we hope to significantly reduce CVD risk.
- 12:04Speaker 1: Agreed, Thomas. The journey ahead is filled with challenges, but
- 12:08Speaker 1: also opportunities. Let's keep the conversation going and support the
- 12:13Speaker 1: development of safer, more effective HDL raising strategies. As we
- 12:17Speaker 1: wrap up today's discussion, let's focus on the strategic implications.
- 12:23Speaker 1: Future innovations in cardiovascular disease, CVD management can't simply rely.
- 12:29Speaker 1: on HDL cholesterol levels, they must consider the broader functions
- 12:33Speaker 1: of HDL in immune function and inflammation. This holistic approach
- 12:39Speaker 1: could lead to more effective therapies.
- 12:41Speaker 2: Absolutely, Rachel. Current research shows that while raising HDL cholesterol
- 12:46Speaker 2: is important, it doesn't tell the whole story. We need
- 12:49Speaker 2: to look at HDL in the context of its roles
- 12:52Speaker 2: in immune regulation and anti-inflammatory responses. For instance, studies have
- 12:57Speaker 2: highlighted that HDL can modulate the immune response by influencing
- 13:02Speaker 2: cytokine production, which plays a key role in cardiovascular health.
- 13:06Speaker 1: That's insightful, Thomas. Let's dig into some specific mechanisms. HDL
- 13:12Speaker 1: can act as an anti-inflammatory agent by reducing the expression
- 13:16Speaker 1: of pro-inflammatory genes in endothelial cells. This is crucial because
- 13:21Speaker 1: chronic inflammation is a major driver of atherosclerosis and CVD.
- 13:26Speaker 1: And with targeted therapies, we could potentially reduce cardiovascular events
- 13:31Speaker 1: by addressing both lipoprotein metabolism and immune function.
- 13:35Speaker 2: Exactly, Rachel. The key here is to develop therapies that
- 13:39Speaker 2: target the multifaceted roles of HDL. For example, we can
- 13:43Speaker 2: explore drugs that enhance the anti-inflammatory properties of HDL without
- 13:48Speaker 2: the adverse effects seen in some nascent inhibitors like torusotrap.
- 13:52Speaker 2: Research is already moving in this direction. with new molecules
- 13:56Speaker 2: designed to boost HDL levels and improve immune function.
- 14:00Speaker 1: We also need to consider patient-specific approaches. Genetic variations can
- 14:06Speaker 1: affect how individuals respond to HDL raising therapies. By understanding
- 14:11Speaker 1: these variations, we can tailor treatments to maximize benefits while
- 14:15Speaker 1: minimizing side effects. This personalized medicine approach could be revolutionary
- 14:21Speaker 1: in CBD management.
- 14:23Speaker 2: Agreed, and it's not just about therapy development. Regulatory bodies
- 14:27Speaker 2: will play a critical role in approving these new approaches.
- 14:31Speaker 2: They need to establish clear guidelines that ensure both efficacy
- 14:34Speaker 2: and safety, while also fostering innovation. This balance will be
- 14:38Speaker 2: crucial as we move forward.
- 14:40Speaker 1: Absolutely. And let's not forget the importance of long-term outcomes.
- 14:45Speaker 1: Chronic conditions like CBD require sustained treatment strategies. so we
- 14:49Speaker 1: must also consider the long-term impacts of these new therapies.
- 14:53Speaker 1: Clinical trials must be designed to monitor patients over extended
- 14:57Speaker 1: periods to fully understand the benefits and risks.
- 15:00Speaker 2: Exactly, Rachel. As we step into the future, a comprehensive
- 15:04Speaker 2: strategy that integrates the multifaceted roles of HDL will be essential.
- 15:08Speaker 2: It's about moving beyond simple cholesterol metrics to focus on
- 15:11Speaker 2: the broader health benefits of HDL. This approach could revolutionize
- 15:15Speaker 2: how we manage and prevent CVD.
- 15:17Speaker 1: That brings us to the end of today's episode. Thank
- 15:20Speaker 1: you so much for spending part of your day with me.
- 15:22Speaker 1: If you found this episode's tips helpful and want to
- 15:25Speaker 1: make sure you don't miss the next conversation, please take
- 15:28Speaker 1: a quick second to hit that subscribe or follow button
- 15:31Speaker 1: on whatever platform you are listening on. It's a completely
- 15:34Speaker 1: free way to support the show and helps more people
- 15:37Speaker 1: find us. This podcast is independently produced, so if you
- 15:41Speaker 1: are ever in a position where you would like to
- 15:43Speaker 1: help keep it running, we do accept small donations. You
- 15:47Speaker 1: can find a link right in the episode description below
- 15:49Speaker 1: to buy us a coffee or contribute what you can.
- 15:53Speaker 1: Every bit genuinely helps. Take care of yourself, stay balanced,
- 15:58Speaker 1: and we will talk again soon.